The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
748
Flibanserin 100mg administered at bedtime for 24 weeks
This is the matched placebo which will be administered two tablets daily at bedtime.
Change From Baseline in the Number of Satisfying Sexual Events
The change from baseline in the number of SSE's as measured by the eDiary. The calculation of Satisfying Sexual Event (SSEs) will be standardized to a 28-day period according to the below formula: Total monthly events = 28 x (sum of the number of events) / (sum of number of days entered). "Satisfying" means gratifying, fulfilling, satisfactory, and/or successful for the patient. The partner's satisfaction is not the subject of this question.
Time frame: baseline to 24 weeks
Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire Domain
The Female Sexual Function Index (FSFI) is a brief, multidimensional, self-administered questionnaire for assessing key domains of sexual function in women. The scale consists of 19 items that assess sexual function over the past four weeks and yields scores in six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The two items in the desire domain are scored from 1 to 5 (1 is lowest level of desire and 5 is the highest level of desire). The raw scores of the two items are added together and then multiplied by the domain factor of 0.6. Thus, the score of the desire domain ranges from 1.2 (lowest level of desire) to 6.0 (highest level of desire). For the entire instrument, each of the six domains contributes a maximum of 6 points to the total. Scores on the full scale range from a minimum of 2 to a maximum of 36.
Time frame: baseline to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
511.156.01059 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States
511.156.01084 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
511.156.01053 Boehringer Ingelheim Investigational Site
Tuscon, Arizona, United States
511.156.01069 Boehringer Ingelheim Investigational Site
Tuscon, Arizona, United States
511.156.01063 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
511.156.01076 Boehringer Ingelheim Investigational Site
Little Rock, Arkansas, United States
511.156.01039 Boehringer Ingelheim Investigational Site
Anaheim, California, United States
511.156.01070 Boehringer Ingelheim Investigational Site
Berkeley, California, United States
511.156.01075 Boehringer Ingelheim Investigational Site
La Mesa, California, United States
511.156.01087 Boehringer Ingelheim Investigational Site
Los Angeles, California, United States
...and 90 more locations